Notice2022-02466
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 7, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 25 (Monday, February 7, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 25 (Monday, February 7, 2022)]
[Notices]
[Pages 6879-6880]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-02466]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Elizabeth Pitts, Ph.D., 240-669-5299;
<a href="/cdn-cgi/l/email-protection#63060f0a19020106170b4d130a171710230d0a0b4d040c15"><span class="__cf_email__" data-cfemail="56333a3f2c373433223e78263f22222516383f3e78313920">[email protected]</span></a>. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement may be required to receive any
unpublished information.
SUPPLEMENTARY INFORMATION: Technology description follows:
Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection
Description of Technology
The ongoing COVID-19 pandemic, caused by severe respiratory
syndrome coronavirus 2 (SARS-CoV-2), has
[[Page 6880]]
created an immense public health, social, and economic burden. Variants
of concern continue to emerge that have increased transmissibility,
pathogenicity, or both and that reduce the effectiveness of current
therapeutics and vaccines. Thus, there is a great need for broadly
protective therapeutics.
This technology relates to two monoclonal antibodies targeting the
spike protein of SARS-CoV-2 that between the two have picomolar
activity against wild-type SARS-CoV-2 and the Alpha, Beta, Delta, and
Omicron variants of concern. Additionally, one of the antibodies
recognizes a highly-conserved epitope of the spike protein. Treatment
with either monoclonal antibody before or after challenge with SARS-
CoV-2 reduced symptoms and viral load in nasal turbinate and lung
tissue in the golden Syrian hamster model. This monoclonal antibody
technology has great potential to treat SARS-CoV-2 infections and may
provide protection against future variants of concern.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications
<bullet> Treatment for SARS-CoV-2 infection
<bullet> Prophylaxis treatment to prevent or reduce SARS-CoV-2
infection
<bullet> Diagnostic for SARS-CoV-2 infection
Competitive Advantages
<bullet> Broad and potent neutralization of several variants of
concern, including Omicron
Development Stage
<bullet> In vivo data assessment (animal)
Inventors: Zhaochun Chen (NIAID); Patrizia Farci (NIAID); Kamille
West (CC); Peng Zhang (NIAID); Paolo Lusso (NIAID); Ulla Buchholz
(NIAID); Yumiko Matsuoka (NIAID).
Intellectual Property: HHS Reference No. E-132-2021- U.S.
Provisional Application No. 63/296,380, filed January 4, 2022.
Licensing Contact: To license this technology, please contact
Elizabeth Pitts, Ph.D., 240-669-5299; <a href="/cdn-cgi/l/email-protection#cbaea7a2b1aaa9aebfa3e5bba2bfbfb88ba5a2a3e5aca4bd"><span class="__cf_email__" data-cfemail="17727b7e6d767572637f39677e63636457797e7f39707861">[email protected]</span></a>, and
reference E-132-2021.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. For collaboration
opportunities, please contact Elizabeth Pitts, Ph.D., 240-669-5299;
<a href="/cdn-cgi/l/email-protection#d5b0b9bcafb4b7b0a1bdfba5bca1a1a695bbbcbdfbb2baa3"><span class="__cf_email__" data-cfemail="690c050013080b0c1d014719001d1d1a29070001470e061f">[email protected]</span></a>.
Dated: February 1, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-02466 Filed 2-4-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 7, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.